Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

KEY TAKEAWAYS The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...